SiegelaarSEBarwariTKulikWHoekstraJBDeVriesHJ. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol.2011;5 (1): 86–92.
2.
Di FlavianiAPicconiFDi StefanoPGiordaniIMalandruccoIMaggioPPalazzoPSgrecciaFPeraldoCFarinaFFrajeseGFrontoniS. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care.2011;34 (7): 1605–9. Epub 2011 May 24.
De CaterinaRCipolloneFFilardoF PZimarinoMBerniniWLazzeriniGBucciarelliTFalcoAMarchesaniPMuraroRMezzettiACiabattoniG. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: No further effect of vitamin E. Circulation.2002;106 (20): 2543–9.
5.
GiaccariASoriceGMuscogiuriG. Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes — Mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis.2009;19 (5): 365–77. Epub 2009 May 9.
6.
ProudfootJBardenAMoriTABurkeVCroftKDBeilinLJPuddeyIB. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem.1999 Aug 1; 272 (2): 209–15.
